1 recruiting, 1 withdrawn. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Recurrent Fallopian Tube Carcinosarcoma: new trials by email Literature Review of Recurrent Fallopian Tube Carcinosarcoma trials Research Report on Recurrent Fallopian Tube Carcinosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-10-31 | 2025-06-03 | |
| MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Recruiting | Mayo Clinic | 12 | 2024-09-20 | 2026-03-16 |
Fallopian Tube Neoplasms (1) · Ovarian Neoplasms (1)
Adnexal Diseases (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Fallopian Tube Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Gonadal Disorders (1) · Neoplasms (1) · Neoplasms by Site (1) · Ovarian Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1)
Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · ASTX-660 (1) · Bendamustine Hydrochloride (1) · Bevacizumab (1) · Cyclophosphamide (1) · Disulfides (1) · Immunoglobulin G (1) · Leukapheresis (1) · Paclitaxel (1) · Taxes (1)
Mayo Clinic (1) · National Cancer Institute (NCI) (1)
United States (1)
Brenda J. Ernst, M.D. (1) · Kristen P Zeligs (1)
U10CA180868 (1)